Initial Testing (Stage 1) of Temozolomide by the Pediatric Preclinical Testing Program

BACKGROUND: The DNA methylating agent temozolomide was developed primarily for treatment of glioblastoma. However, preclinical data have suggested a broader application for treatment of childhood cancer. Temozolomide was tested against the PPTP solid tumor and ALL models. PROCEDURES: Temozolomide wa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pediatr Blood Cancer
Asıl Yazarlar: Keir, Stephen T., Maris, John M., Reynolds, C. Patrick, Kang, Min H., Kolb, E. Anders, Gorlick, Richard, Lock, Richard, Carol, Hernan, Morton, Christopher L., Wu, Jianrong, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4244112/
https://ncbi.nlm.nih.gov/pubmed/23335050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24368
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller